New York Times — Most high-risk men don’t take PrEP to prevent H.I.V.
Among men who are at high risk for H.I.V. infection, only about one in three is taking a drug to prevent transmission of the virus, according to a survey from the Centers for Disease Control and Prevention. The drug, Truvada, is taken daily as part of a preventive strategy called pre-exposure prophylaxis, or PrEP.

Bloomberg — Climate change may draw $200 billion vaccine boom, analyst says
Higher temperatures across the globe could expose almost a billion more people to risks for diseases like Zika and Ebola by 2080 and that may be a boon for some drugmakers, Morgan Stanley tells investors.

Eurekalert! — Tobacco-21 laws can lower smoking prevalence in the 18-20 age group
A new study published today by the scientific journal Addiction found that raising the legal age of sale of cigarettes from 18 to 21 in the U.S. was associated with a 39% reduction in the odds of regular smoking in 18- to 20-year-olds who had experimented with cigarettes. The reduction was even greater (50%) in those who had close friends who smoked when they were 16.

Science Daily — Half of young drinkers are unaware of health messages on alcohol packaging
Just half of 11-19 year old drinkers recall seeing health messages or warnings on alcohol packaging — despite being an important target market for this information, according to new research.

National Institutes of Health — NIH establishes network to improve opioid addiction treatment in criminal justice settings
The National Institutes of Health will award 12 grants to form the Justice Community Opioid Innovation Network (JCOIN) to support research on quality addiction treatment for opioid use disorder (OUD) in criminal justice settings nationwide. The awards, totaling an estimated $155 million from the National Institute on Drug Abuse, part of NIH, will support the multi-year innovation network, including 10 research institutions and two centers that will provide supportive infrastructure.